Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.T3D Therapeutics has obtained exclusive global rights to develop and commercialize oral, highly selective, dual nuclear receptor agonist DB959 from DARA BioSciences.
Subscribe to our email newsletter
Targeting peroxisome proliferator activated receptor delta (PPARd), DB959 was developed by DARA through Phase 1 trials for the treatment of diabetes and dyslipidemia.
As per the company’s strategic plan to focus on the commercialization of oncology supportive care products, DARA planned to out-license DB959.
DARA chief executive officer and chief medical officer David Drutz said, "This program no longer fits into the strategic focus of DARA as we have shifted our corporate attention to the commercialization of oncology supportive care products."
T3D Therapeutics founder and chief executive officer John Didsbury said, "Given the neuroprotectant potential of DB959’s mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development program for DB959."